Source: Pharmacy Times articles
Sanofi’s SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes.
by MM360 Staff | Aug 1, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
Sanofi’s SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes.